The partnership will apply near infrared imaging technology with Kent’s KD203 tissue oxygenation assessment device to improve tissue assessment in wounds.

Kent Imaging CEO Pierre Lemire said: “Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds.”

Kent’s KD203 is a cordless handheld portable device for use in all care setting , and provides instant tissue assessment.

The device also offers quantified tissue oxygenation levels, as well as accurate and unlimited imaging and storage flexibility.

Healthcare professionals can use Kent’s device as a non-invasive tissue oxygenation measurement system, which reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue.

Kent’s multispectral imaging technology shows two-dimensional color-coded images, providing significant information to help clinicians find out risk tissue and guide treatments to optimize patient outcomes in wound care, plastic surgery and various other reconstructive applications.

SerenaGroup will take Kent’s technology as the standard of care for evaluating wound oxygenation.

Kent will be incorporated into each of the SerenGroup’s managed facilities, included in hyperbaric training courses curriculum and future clinical and preclinical research.

SerenaGroup founder and medical director Dr Serena said: “We are pleased to introduce Kent’s imaging system into the wound care protocol at our clinics. One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue.”

Based in Calgary off Alberta, Kent Imaging is engaged in the designing, manufacturing and marketing of imaging technology for wound and surgical care.

SerenaGroup, which is engaged in wound healing research, has conducted more than 100 clinic trials in collaboration with the nation’s first wound healing cooperative group.